<DOC>
	<DOC>NCT01271010</DOC>
	<brief_summary>This multi-center, single-arm study will evaluate the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.</brief_summary>
	<brief_title>A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis of previously untreated Bcell CLL confirmed immunophenotypically For participants, age 6070 years: Cumulative Illness Rating Scale (CIRS) comorbidity score less than or equal to (&lt;/=) 6 Binet stage B, C or A with progression Life expectancy greater than or equal to (&gt;/=) 12 months Eastern Cooperative Oncology Group (ECOG) performance status (PS) 02 Women of child bearing potential and men should agree to use highly reliable contraceptive method throughout the treatment period and within 12 months after treatment completion Participants with smallcell lymphoma Participants with autoimmune hemolytic anemia Concomitant malignant disease during enrollment, except basal cell carcinoma of the skin Chemotherapy for concomitant malignant disease given within 12 months prior to study enrollment Participants with Richter's Syndrome Participants with symptomatic Hepatitis B infection Any clinically significant infection that could not be cured prior to enrollment, including Human Immunodeficiency Virus (HIV) infection Creatinine clearance less than (&lt;) 30 milliliters per minute (mL/min) Participants with congestive heart failure (CHF) New York Heart Association (NYHA) IIIIV Participants with liver failure and acute hepatitis of any etiology Any other medical or mental condition which may preclude from receiving the entire course of protocol specified treatment or signing the informed consent History of an anaphylactic reaction to murine antibodies, proteins, or any other ingredient of rituximab Pregnancy and breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>